Rare eye condition
Leber congenital amaurosis in adults
Leber congenital amaurosis (LCA) causes severe visual impairment from infancy; adults living with LCA now have new reasons to seek genetic confirmation, including approved gene therapy for the RPE65 form.
Key points
The essentials at a glance.
What to look out for, how the diagnosis is confirmed, who looks after it, and the options that exist.
-
01
LCA is the most severe of the inherited retinal dystrophies, usually evident in the first year of life.
-
02
More than 25 genes cause LCA; the specific gene shapes prognosis and, increasingly, treatment options.
-
03
Adults diagnosed clinically decades ago often never had genetic testing - modern panels can now identify the cause.
-
04
Voretigene neparvovec (Luxturna) is approved for RPE65-related disease where viable retinal cells remain.
-
05
Specialist inherited retinal disease clinics can re-evaluate adults, arrange testing and assess gene-therapy eligibility.
Understanding it
What it is, and what happens next.
In plain English - what is going on, how specialists confirm it, and the routes to treatment in the UK.
Many adults with Leber congenital amaurosis were diagnosed in childhood on clinical grounds alone, long before genetic testing existed, and have had little contact with eye services since. The landscape has changed: identifying the responsible gene now carries practical consequences, from family planning advice to eligibility for treatment.
A referral to an inherited retinal disease clinic is worthwhile at any age: panel testing through the NHS Genomic Medicine Service can identify the gene, and for the RPE65 subgroup an approved gene therapy exists provided enough retinal tissue survives - something modern imaging can assess even in eyes with very poor vision. In many parts of the UK, routine NHS outpatient referrals for problems like this can take several months, whereas an initial appointment with a private consultant is typically available within around two weeks.
A quiet reminder
This guide is for information, not medical advice.
Your GP or specialist knows your history and can tell you which parts apply to you. If in doubt, speak to them.
Published 2026-09-27 · Next review 2027-09-27
Frequently asked
Common questions about Leber congenital amaurosis in adults.
Quick, plain-English answers to what people ask us most.
-
What is Leber congenital amaurosis?
Leber congenital amaurosis is a rare inherited retinal condition causing severe vision loss from birth or early infancy, due to abnormal development or function of the light-sensing cells in the retina. It's one of the most common causes of inherited blindness in children, but affected individuals live into adulthood with the condition.
-
What causes Leber congenital amaurosis?
It's caused by mutations in one of several genes essential for normal retinal function, most inherited in an autosomal recessive pattern, meaning both parents carry a copy of a faulty gene. Identifying the specific gene involved is important as it affects prognosis and treatment options.
-
What are the symptoms of Leber congenital amaurosis in adults?
Adults living with the condition typically have severe, longstanding vision impairment or blindness present since infancy, sometimes with light sensitivity, nystagmus (involuntary eye movements), and other associated eye findings. The degree of vision loss varies depending on the specific genetic cause.
-
Is Leber congenital amaurosis dangerous?
It doesn't affect general health or life expectancy, but it does cause significant, usually lifelong visual impairment. Some specific genetic subtypes may be associated with other health issues that need monitoring, depending on the gene involved.
-
Is Leber congenital amaurosis genetic?
Yes, it's a genetic condition, and genetic testing to identify the specific gene involved is important because it can determine eligibility for specific treatments, including gene therapy for certain gene mutations. Genetic counselling is recommended for affected families.
-
Can Leber congenital amaurosis be treated?
For a specific gene mutation (RPE65), a licensed gene therapy (Luxturna) can improve vision in appropriately selected patients. For other gene mutations, there's currently no curative treatment, though supportive low-vision services and ongoing research into further gene therapies offer hope.
-
How is Leber congenital amaurosis managed as an adult?
Management includes regular ophthalmology monitoring, genetic testing to identify the specific mutation and check treatment eligibility, and access to low-vision support services and visual aids. Ongoing research means new treatment options continue to develop for specific genetic subtypes.
-
How does Leber congenital amaurosis affect quality of life for adults?
The impact varies considerably depending on the degree of vision loss, but many adults with the condition lead full, independent lives with appropriate visual aids, technology and support services. Early access to low-vision rehabilitation services makes a significant difference.
-
Leber congenital amaurosis vs other inherited retinal dystrophies — what's the difference?
Leber congenital amaurosis specifically causes severe vision loss from birth or very early infancy, whereas other inherited retinal dystrophies, such as retinitis pigmentosa, typically cause more gradual vision loss starting later in childhood or adulthood. Genetic testing helps distinguish between these related but distinct conditions.
-
When should an adult with Leber congenital amaurosis seek specialist review, and how quickly can this be arranged privately?
Regular ophthalmology review is recommended to monitor eye health and check for eligibility for any new treatments as they become available. Private ophthalmology and genetics consultations can typically be arranged within about two weeks, considerably faster than standard NHS waiting times.